Stephen Machatha sold $99k of ALDX
Chief Development Officer at Aldeyra Therapeutics, Inc.. 29,768 shares at an average of $3.31, traded Mar 11, 2024, filed Mar 12, 2024.
Score components
- +15RoleOfficer
- +10Trade size$99k at market
- +5Share of holdings soldSold 11% of holdings
- +15Cluster3 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-24-030311, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 11, 2024 | SOpen-market sale Common Stock | -18,231 | $3.41 | $62k | 255,032 | Mar 12, 2024 |
| Mar 12, 2024 | SOpen-market sale Common Stock | -11,537 | $3.16 | $37k | 243,495 | Mar 12, 2024 |
| Mar 9, 2024 | AGrant or award Stock Option (right to buy)derivative | +405,450 | $0.00 | $0 | 405,450 | Mar 12, 2024 |
Related signals
Other insiders at Aldeyra Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 52Moderate | ALDXbuy Aldeyra Therapeutics, Inc. | Todd C Brady President and CEO | $418k 250,000 shares | +17% | |
| 51Moderate | Aldeyra Therapeutics, Inc. | Richard Douglas director | $98k 70,000 shares | +56% | |
| 41Moderate | Aldeyra Therapeutics, Inc. | Michael Alfieri Principal Financial Officer | $7,100 5,000 shares | +200% | |
| 27Weak | ALDXbuy Aldeyra Therapeutics, Inc. | Michael Alfieri Principal Financial Officer | $13k 2,500 shares | - | |
| 25Weak | ALDXsell Aldeyra Therapeutics, Inc. | Stephen Machatha Chief Development Officer | $114k 22,073 shares | -9% | |
| 47Moderate | ALDXsell Aldeyra Therapeutics, Inc. | Perceptive Advisors LLC owner | $4.8M 3,400,000 shares | -37% | |
| 23Weak | ALDXbuy Aldeyra Therapeutics, Inc. | Nancy Miller-Rich director | $10k 922 shares | - | |
| 43Moderate | ALDXbuy Aldeyra Therapeutics, Inc. | Perceptive Advisors LLC owner | $834k 177,993 shares | +2% | |
| 43Moderate | ALDXbuy Aldeyra Therapeutics, Inc. | Perceptive Advisors LLC owner | $1.9M 504,272 shares | +6% | |
| 64Notable | Aldeyra Therapeutics, Inc. | Todd C Brady President and CEO | $581k 183,238 shares | -11% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.